RxDoctor Payments Data

Dennis Matzkin, MD

Ophthalmology · Chattanooga, TNNPI 1912968371

Payments from drug & device makers

$3,389in general payments, 2019–2025

Across 84 payments — averaging $40.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$354
  • Johnson & Johnson Surgical Vision, Inc.$258
  • Regeneron Healthcare Solutions, Inc.$174
  • Genentech USA, Inc.$165
  • Glaukos Corporation$150
  • plus $759 from 12 others

What the payments were for

  • Travel & lodging$171%
  • Food & beverage$3,33898%
  • Entertainment$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,389 in reported general payments places this provider in the 65th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$957,840
Medicare patients
919
Services billed
11,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine22$25,590
Prednisolone Acetate359$15,860
CombiganBrimonidine Tartrate/Timolol36$14,296
VyzultaLatanoprostene Bunod22$10,696
LumiganBimatoprost13$10,148
Latanoprost631$6,880
Acetazolamide36$5,337
Fluorometholone78$5,228
Ketorolac Tromethamine230$4,907
Loteprednol Etabonate34$4,622
Cyclosporine12$4,327
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$3,214
Ofloxacin253$2,900
Lotemax SmLoteprednol Etabonate11$2,657
ValacyclovirValacyclovir Hcl43$2,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$354$50,03471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →